Russians are facing a shortage of the oncology drug uromitexan in pharmacies. The newspaper reports this “Vedomosti” citing a source at the pharmacy chain.
This drug is available in Moscow, Moscow region, St. It is stated that it disappeared from pharmacies in St. Petersburg and the Leningrad region, Novosibirsk, Izhevsk, Saratov, Samara, Volgograd and other cities.
Roszdravnadzor reported that in October last year, the manufacturer of uromitexan announced that it would send to Russia only products produced in line with previously received orders.
In 2023, 6.9 thousand packages of uromitexan (56.7 thousand in 2022) entered the country. The last deliveries took place in April.
Experts interviewed by the newspaper believe that Baxter decided to withdraw the drug from the Russian market for economic reasons. RNC Pharma explained that worldwide drug production is increasing due to inflation and increasing logistics costs, but in Russia it is impossible to quickly increase the price of uromitexane due to its inclusion in the list of vital and essential medicines (VED). Development Director Nikolai Bespalov.
existed before named Medicines that have left the Russian market and have no analogues.